| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $2,799,748 ) |
| | 2025 | 2025 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | UM1AI108568 | The Military HIV Research Program (MHRP) Clinical Trial Unit | 002 | 12 | NIH | 1/10/2025 | $692,302 |
| | 2025 | 2025 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01CA255232 | Isoform-specific signaling as a determinant of RAS-driven oncogenesis | 000 | 4 | NIH | 3/6/2025 | $313,951 |
| | 2025 | 2025 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21AI173847 | RNA and DNA sensors in the response of macrophages to ionizing radiation | 000 | 2 | NIH | 4/1/2025 | $199,469 |
| | 2025 | 2025 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | UM1AI108568 | The Military HIV Research Program (MHRP) Clinical Trial Unit | 002 | 12 | NIH | 1/10/2025 | $154,654 |
| | 2025 | 2025 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01NS119594 | Calcium Dysregulation and Cell Function in Spinal Muscular Atrophy | 000 | 5 | NIH | 2/17/2025 | $343,117 |
| | 2025 | 2025 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01HL167048 | COVID-19 airway inflammation is due to Spike inhibition of CFTR signaling | 000 | 3 | NIH | 1/9/2025 | $571,842 |
| | 2025 | 2025 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21AI190739 | Delineating the kinetics of spinal pathology in the EV-D68 infected ferret model | 000 | 1 | NIH | 2/1/2025 | $217,976 |
| | 2025 | 2025 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R35GM139619 | Temporal and Metabolic Regulation of Restimulation-Induced Cell Death (RICD) in Human T Cells | 001 | 5 | NIH | 12/9/2024 | $343,117 |
| | 2025 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R35GM140792 | Regulation of cytoplasmic dynein in vivo | 000 | 4 | NIH | 12/2/2024 | $0 |
| | 2025 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R35GM139619 | Temporal and Metabolic Regulation of Restimulation-Induced Cell Death (RICD) in Human T Cells | 000 | 4 | NIH | 11/4/2024 | $0 |
| | 2025 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21AR081008 | Does joint lavage reduce intraarticular inflammation in high-energy tibial pilon fractures? | 000 | 3 | NIH | 10/25/2024 | $0 |
| | 2025 | 2023 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01CA252468 | ATR Dependency as a Novel Therapeutic Target in Lethal RB Deficient ProstateCancer | 003 | 6 | NIH | 2/19/2025 | $170,502 |
| | 2025 | 2023 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | K01OD031900 | Assessing if distinct susceptibility to neutralization of cell-free and cell-to-cell spread impacts antibody conferred protection from SHIV infection | 000 | 3 | NIH | 3/13/2025 | $0 |
| | 2025 | 2023 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21AI171791 | Host Ca2+, actin, and ATP production in rickettsia-endothelial cell dysfunction | 000 | 2 | NIH | 1/30/2025 | $0 |
| | 2025 | 2023 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01AI141961 | Role of the enterococcal site 2 protease in biofilm formation, adaptation, and host-pathogen interactions | 000 | 5 | NIH | 1/14/2025 | $0 |
| | 2025 | 2022 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01GM127938 | Clu forms a dynamic new ribonucleoprotein particle directly involved in mitochondrial function | 000 | 4 | NIH | 2/28/2025 | $0 |
| | 2025 | 2022 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21CA257484 | Identifying EZH2-dependent vulnerabilities in RB deficient prostate cancer | 001 | 3 | NIH | 3/28/2025 | -$181 |
| | 2025 | 2022 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01HL126727 | Induction of tolerance to FVIII by engineered T regulatory cells in hemophilia | 000 | 8 | NIH | 11/23/2024 | -$67,661 |
| | 2025 | 2022 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21OD030163 | Advanced Image Analysis Tools for Super-Resolved MRI in Small Animals | 000 | 2 | NIH | 10/25/2024 | -$162 |
| | 2025 | 2022 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21AI164407 | Role of primaquine pharmacokinetics in treatment efficacy for vivax malaria | 000 | 1 | NIH | 10/23/2024 | -$139,178 |
| | 2025 | 2022 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21CA257484 | Identifying EZH2-dependent vulnerabilities in RB deficient prostate cancer | 000 | 3 | NIH | 10/23/2024 | $0 |
| | 2025 | 2021 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01AI125552 | T cell receptor-activated autophagy as a regulator of T cell effector responses | 000 | 5 | NIH | 1/13/2025 | $0 |
| | 2025 | 2021 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21AI152076 | Development of the ferret model for EV-D68 infection | 000 | 2 | NIH | 2/5/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $17,148,817 ) (Continued on the next page) |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21NS136126 | Inflammation and white matter microstructural alterations after OP exposure | 001 | 1 | NIH | 9/16/2024 | $0 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21AI173635 | HTLV-1 Replication/Reactivation-Induced DNA Damage: Mechanisms and Pathogenesis | 001 | 2 | NIH | 11/27/2023 | $0 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01HL167048 | COVID-19 airway inflammation is due to Spike inhibition of CFTR signaling | 000 | 2 | NIH | 12/22/2023 | $527,792 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21AI173635 | HTLV-1 Replication/Reactivation-Induced DNA Damage: Mechanisms and Pathogenesis | 002 | 2 | NIH | 5/10/2024 | $18,983 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21AI173635 | HTLV-1 Replication/Reactivation-Induced DNA Damage: Mechanisms and Pathogenesis | 000 | 2 | NIH | 10/24/2023 | $170,845 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | U01AI170033 | Mitigation of Radiation Induced Immune Dysfunction by PrC-210 Treatment | 000 | 3 | NIH | 5/8/2024 | $476,834 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21AI173847 | RNA and DNA sensors in the response of macrophages to ionizing radiation | 001 | 1 | NIH | 9/11/2024 | $23,936 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21AI173847 | RNA and DNA sensors in the response of macrophages to ionizing radiation | 000 | 1 | NIH | 5/14/2024 | $215,427 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01AI147627 | Plasmodium falciparum gametocytogenesis in vitro and in vivo | 001 | 5 | NIH | 5/21/2024 | $49,866 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01AI147627 | Plasmodium falciparum gametocytogenesis in vitro and in vivo | 000 | 5 | NIH | 11/24/2023 | $448,809 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21MH132136 | Intrinsic CRF signaling within the lateral habenula | 001 | 2 | NIH | 8/14/2024 | $18,983 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21MH132136 | Intrinsic CRF signaling within the lateral habenula | 000 | 2 | NIH | 2/27/2024 | $170,845 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21CA267515 | Preventing Therapeutic Resistance in RAS-mutated Pediatric Cancers | 000 | 3 | NIH | 1/16/2024 | $164,671 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01GM114173 | Evolution of Homologous Recombination Mechanisms | 000 | 8 | NIH | 2/16/2024 | $279,194 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | U01OH012485 | Grief and health-related quality of life in WTCHR Survivors: Associations with bereavement, trauma exposures, and mental and physical health conditions | 00 | 3 | CDC | 4/2/2024 | $499,343 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R00HD099520 | Molecular analysis of MEHMO syndrome mutations in translation factor eIF2 | 001 | 4 | NIH | 5/6/2024 | $22,051 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R00HD099520 | Molecular analysis of MEHMO syndrome mutations in translation factor eIF2 | 000 | 4 | NIH | 11/14/2023 | $220,513 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01GM114173 | Evolution of Homologous Recombination Mechanisms | 002 | 8 | NIH | 7/24/2024 | $31,021 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01GM114173 | Evolution of Homologous Recombination Mechanisms | 001 | 8 | NIH | 5/31/2024 | $65,582 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R35GM139619 | Temporal and Metabolic Regulation of Restimulation-Induced Cell Death (RICD) in Human T Cells | 000 | 4 | NIH | 12/11/2023 | $343,117 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21OD034471 | Identifying the radioprotective potential of radiation-resistant fungi using Drosophila | 000 | 1 | NIH | 7/25/2024 | $239,363 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | UM1AI108568 | The Military HIV Research Program (MHRP) Clinical Trial Unit | 002 | 11 | NIH | 11/2/2023 | $134,429 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | UM1AI108568 | The Military HIV Research Program (MHRP) Clinical Trial Unit | 002 | 11 | NIH | 11/2/2023 | $639,502 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R03HD114176 | Quantifying Locomotor Outcomes with Agonist-Antagonist Myoneural Interface | 001 | 1 | NIH | 9/25/2024 | $0 |
| | 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R03HD114176 | Quantifying Locomotor Outcomes with Agonist-Antagonist Myoneural Interface | 000 | 1 | NIH | 7/26/2024 | $240,722 |
|
